TTTech Industrial Acquires Nebbiolo Technologies Business and Sets up Subsidiary in Silicon Valley
25.5.2021 11:00:00 EEST | Business Wire | Press release
TTTech Industrial Automation AG has acquired core technology and strategic customers from pioneering fog/edge computing start-up Nebbiolo Technologies in a deal closed in May. Integrating features and know-how from Nebbiolo Technologies will support TTTech Industrial’s commitment to delivering the world’s most advanced industrial edge computing platform to its customers. TTTech Industrial has also founded a US subsidiary in Silicon Valley to expand its activities in the North American market. Kannan Devarajan, one of the co-founders of Nebbiolo Technologies has joined TTTech Industrial North America Inc. as Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005037/en/
“The integration of assets from Nebbiolo Technologies enables us to offer even more advanced industrial edge computing solutions to new and existing customers in a wider range of application fields.” Thomas Berndorfer, Member of the Executive Board, TTTech Industrial Automation AG (© TTTech Industrial Automation AG)
TTTech Industrial is a leading provider of industrial IoT solutions, and partners with key players in IoT such as Intel and Microsoft. The company’s Nerve software platform has been at the forefront of industrial edge computing since its launch in 2016. The foundation of TTTech Industrial North America supports the expansion of commercial operations in the US and Canada, with the technology and customer assets acquired from Nebbiolo Technologies forming the nucleus of these activities.
Nebbiolo Technologies is renowned as the pioneer of fog computing, with patented technology that is foundational to industrial edge computing concepts. The company was named a Gartner Cool Vendor in 2017 and was recognized as the Customer Value Leader in the IIoT edge computing market by Frost & Sullivan in 2019. The combination of existing Nerve product features with Nebbiolo Technologies’ expertise will provide customers with an unparalleled solution for software management at the edge, remote connectivity, edge analytics, high-availability, and security.
TTTech Industrial has an existing customer base of machine builders and system integrators based in Europe, the US and Asia. Aside from growing its operations in North America and Asia, this deal also allows TTTech Industrial to widen the scope of its activities to new industries such as energy, oil/gas and auto manufacturing, strengthen the global reach of its edge computing solutions and bolster go-to-market activities in Europe.
"The launch of our US subsidiary marks a significant step for our company. Our location in Silicon Valley brings us closer to customers and allows us to tap into a pool of the world's best software engineering talent. The integration of assets from Nebbiolo Technologies enables us to offer even more advanced industrial edge computing solutions to new and existing customers in a wider range of application fields,” explains Thomas Berndorfer, Member of the Executive Board, TTTech Industrial Automation AG.
“I am very proud to be leading TTTech Industrial's expansion into North America. My team and I bring a wealth of experience in edge computing solutions that will contribute to making Nerve the platform of choice for industrial automation customers. In addition, we will provide customers with expert local sales and technical support, as well as custom feature development," says Kannan Devarajan, Managing Director, TTTech Industrial North America.
CEO and co-founder of Nebbiolo Technologies Chandra Joshi states, “We have been partnering with TTTech Industrial from the outset of our journey. I am confident that the integration of Nebbiolo’s technology with TTTech Industrial’s Nerve product line will create a leading-edge computing platform to enable existing and new customers to accelerate their digital transformation.”
About TTTech Industrial Automation AG
TTTech Industrial aspires to unlock the incredible potential of industrial automation. It combines transformative technologies with hands-on experience in critical real-time systems to offer customers flexibility, reliability and choice. TTTech Industrial operates under the umbrella of the TTTech Group, a leading provider of safe networked computing platforms, with cross-industry experience from more than 20 years of operation.
TTTech Industrial product lines Nerve, Slate and Flexibilis are designed to converge and connect automation systems. Nerve is a flexible, open industrial edge computing platform that enables users to access data, manage devices and deploy applications remotely. Slate is a deterministic networking platform that provides comprehensive TSN solutions. Flexibilis is a redundant networking product portfolio that delivers high-availability seamless redundancy for a wide range of industrial applications, most notably in the energy industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005037/en/
Contact information
Press
Judith Lebic
External Communications
Tel: +43 1 585 34 34-0
E-mail: pr@tttech-industrial.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom